Delta-9-tetrahydrocannabinol is the most studied molecule in the plant and the one the package shouts about. The surface version is simple: THC gets you high. The deeper version is where the useful knowledge lives, because almost everything that goes right or wrong with THC is a function of dose, receptor binding, and who is doing the consuming.
How it works
THC is a partial agonist at the CB1 receptor — the receptor densely expressed in the brain regions that govern mood, memory, pain perception, appetite, and motor coordination. When THC binds CB1, it nudges those systems off baseline. That nudge is the high: time dilation, appetite, euphoria, the giggles, the couch. Because THC only partially activates the receptor, its effect curve is not linear — more is not simply more.
The biphasic curve (why the same drug calms and panics)
THC is biphasic: low doses and high doses produce opposite effects on the same axis. A low dose tends to reduce anxiety and lift mood. Past a personal threshold, the same compound flips and drives anxiety, racing thoughts, and in some cases acute paranoia. The difference between "relaxed" and "why is my heart doing that" is often two or three milligrams, not a question of willpower or tolerance to tough it out.
The most common bad cannabis experience is not a bad product. It is a good product at the wrong dose for that person, that day.
The medical track record is real
This is not folklore. Dronabinol (synthetic THC) and nabilone are FDA-approved pharmaceuticals for chemotherapy-induced nausea and vomiting[2]. THC went through controlled trials and earned approval because the molecule reliably does something measurable[6]. The open scientific questions were never "does it work" — they are "at what dose, by what route, in whom, with what risk."
What to watch for
Acute: short-term memory and coordination impairment while THC is active. Temporary in adults. Do not drive.
Developmental: heavy, frequent use during adolescence is associated with persistent cognitive effects, because the developing brain is remodeling the exact systems THC acts on.
Psychiatric: in people with a predisposition to psychotic disorders, high-THC products used frequently can worsen and accelerate outcomes — covered in full in the Cannabis & Mental Health dive.
The Endocannabinoid System — The Engine Cannabis Plugs Into
Full Entry
You cannot actually understand cannabis without understanding the system it acts on — and that system is not in the plant. It is in you. The endocannabinoid system (ECS) was discovered through cannabis research in the early 1990s, and it turns out to be one of the body’s master regulators. Skipping it is like teaching someone to drive without mentioning the engine.
The two receptors
CB1 is concentrated in the brain and central nervous system — mood, memory, pain, appetite, motor control. CB2 sits mostly on immune cells and in the gut — inflammation and immune response. Plant cannabinoids work because they interact with these receptors your body already built. THC fits CB1 like a loud key. CBD works more indirectly, which is why it doesn’t intoxicate.
Your body makes its own cannabinoids
Two of them, primarily. Anandamide — named from the Sanskrit for "bliss" — was the first identified. 2-AG is roughly a thousand times more abundant in the brain. Together they run on demand: when a system drifts out of range, the ECS releases these molecules to pull it back[2]. This is homeostasis, and the ECS is one of its main control surfaces.
The "runner’s high" long blamed on endorphins is now attributed largely to anandamide. You are running your own cannabinoid system every day. Cannabis just visits it.
Why this matters for consumers
Once you see the ECS, the rest of the education section stops being a list of random compounds and becomes a map. THC over-activates CB1. CBD modulates the system sideways. Exercise and omega-3 fatty acids raise your own endocannabinoid tone. Tolerance, the munchies, why edibles hit differently — all of it traces back to this one regulatory system. Understand the engine, and every other page reads faster.
Cannabis & Mental Health — Benefits, Risks, and the Predisposition Question
Full Entry
This is the deep dive the industry would rather not publish, because it refuses to pick a side. Cannabis genuinely helps a great many people manage anxiety, sleep, PTSD, and mood — and cannabis genuinely raises risk for a smaller group whose biology is wired differently. Both are true. An honest educator holds both at once.
The benefit, taken seriously
Large numbers of people, many of them neurodivergent, report that cannabis outperforms medications they have tried. That lived experience is data, not delusion, and dismissing it with a "pothead" stereotype has done real damage to the conversation and to the people in it.
The risk, taken seriously
The link between cannabis and the schizophrenic spectrum is one of the more consistent findings in the literature[5]. For people with a predisposition — diagnosed or latent — high-THC cannabis used frequently in adolescence and young adulthood is associated with earlier onset and greater severity of psychotic illness. Cannabis does not create the predisposition. It can pull the trigger on one that is already loaded.
Cannabis does not cause schizophrenia in people without the vulnerability. It can activate and amplify one that already exists. Family history is the strongest signal you have.
What responsible use looks like
Know your family history. Treat high-THC, high-frequency, adolescent-age use as the highest-risk combination. Watch your own pattern honestly — whether it is serving you or running you. And understand that the same molecule that quiets one person’s anxiety can worsen another person’s illness. Individual biology is the variable that decides the outcome.
If you or someone you know is struggling: in Canada and the U.S., call or text 988. Internationally, findahelpline.com.
Cannabidiol is the second most abundant cannabinoid in most cannabis, and it does not intoxicate. It arrived in the public eye as a remedy for nearly everything, and the reality is more measured and more interesting than the marketing.
How it works
Unlike THC, CBD does not strongly bind the CB1 receptor. It influences the endocannabinoid system indirectly and acts on several non-cannabinoid targets involved in inflammation, pain signalling, and neural excitability. That indirect mechanism is why its effects are subtler and harder to reduce to a single tagline.
The proven win
Epidiolex, a plant-derived CBD medication, is approved for severe childhood epilepsy syndromes (Dravet and Lennox-Gastaut). This is clinical-trial evidence, not anecdote — the compound reliably reduces seizure frequency in patients who had run out of options[2].
The dose gap, and the interaction every patient should know
Most wellness products contain CBD at a fraction of the doses studied in epilepsy trials, so the evidence base for a 25 mg gummy is thinner than the packaging implies. More important: CBD inhibits liver enzymes (CYP3A4, CYP2C19) that metabolize many common drugs — blood thinners, some heart medications, certain antidepressants. If you take prescription medication, this is a conversation with your pharmacist, not a footnote[7].
CBN (cannabinol) is what THC becomes as it ages and oxidizes. It is mildly psychoactive — a fraction of THC’s potency — and the market has positioned it as the “sleep cannabinoid.” The evidence is early and worth reading carefully.
What the research actually shows
A 2024 controlled trial reported improved sleep quality across doses versus placebo — encouraging. But a separate study found CBD isolate produced similar sleep benefits, which complicates the claim that CBN is uniquely responsible. Was it CBN specifically, or mild sedation from cannabinoid interaction generally? The research is not yet mature enough to say.
The honest position
CBN sits in “clinical interest,” not “clinical proof.” That is a legitimate stage of the scientific process; it is simply not the same as settled evidence. The products on the shelf are ahead of the data, which is common in this industry. We will update this entry as the trials accumulate.
CBG earns its nickname through chemistry, not marketing. Cannabigerolic acid (CBGA) is the precursor from which the plant synthesizes the acids that become THC, CBD, and CBC. Without it, the major cannabinoids do not exist.
What the preclinical work suggests
CBG is non-intoxicating. Laboratory and animal research has flagged anti-inflammatory, antibacterial (notably against MRSA), and possible neuroprotective activity. The antibacterial findings in particular have drawn serious interest from researchers working on antibiotic-resistant infections.
The necessary caveat
Almost all of this evidence is preclinical — cell cultures and animal models, not human trials. Compounds that look promising in a dish routinely fail in people. “Mother cannabinoid” describes CBG’s place in the plant’s chemistry, not a proven therapeutic rank. The distinction is the whole point of honest education.
THCV resembles THC with a shorter molecular tail, and that small change gives it a different personality. At low doses it blocks the CB1 receptor; at higher doses it can activate it. That switch between antagonist and agonist is unusual and explains much of the research interest.
The metabolic angle
THCV suppresses appetite — the pharmacological opposite of the “munchies” — and early human work suggests improved insulin sensitivity, with one trial in type 2 diabetics showing reduced fasting glucose. These are measurable clinical endpoints, not a weight-loss supplement claim.
The supply reality
THCV is naturally rare; most strains carry only trace amounts, with certain African landraces (Durban Poison is the common example) higher. Breeding and biosynthesis may solve supply over time, but for now genuine high-THCV products are uncommon and expensive. If a label claims significant THCV, check the lab results[2].
Consumption Methods — Pharmacokinetics, Not Preference
Full Entry
How you take cannabis is not a lifestyle choice; it is pharmacokinetics. The same compound, delivered differently, produces different onset, duration, and intensity — and in the case of edibles, a different active molecule.
Inhalation
Onset 6–10 minutes, duration 2–3 hours. Rapid delivery lets you titrate in near real time. The trade-off is combustion: smoking produces irritants; vaporizing at controlled temperatures reduces them substantially[2].
Edibles
Onset 30 minutes–2 hours, duration 4–8 hours. The liver converts delta-9-THC into 11-hydroxy-THC, a different and often more intense molecule. The delayed onset is why re-dosing too early is the most common edible mistake. “Start low, go slow” is chemistry, not caution for its own sake.
Sublingual, topical, and transdermal
Sublingual products aim for mucosal absorption (15–60 minutes) but often partly swallow into an oral timeline. Topicals act locally and do not intoxicate. Transdermals are engineered to cross the skin into systemic circulation and can intoxicate — a distinction the market frequently blurs. If the label says transdermal, it means systemic.
Concentrates strip away plant material to deliver cannabinoids and terpenes at high potency. They are not inherently dangerous and not a beginner’s default; the method, source, and post-processing determine what you are actually consuming.
Solventless
Dry sift and kief separate trichomes mechanically. Ice-water hash uses cold and agitation, filtered through fine mesh and graded on a star system. Rosin applies heat and pressure — what goes in is what comes out. Live rosin, made from fresh-frozen material, preserves the volatile terpenes that drying would lose, and currently sits at the top of the solventless market.
Solvent-based
BHO uses butane and is purged under heat and vacuum, yielding shatter, budder, crumble, sauce, or diamonds depending on finishing. CO2 extraction is cleaner and common for cartridges. Ethanol scales efficiently for distillate and edibles, with less terpene preservation.
Distillate vs. full-spectrum
Distillation refines extract to 85–95% pure cannabinoid — a blank slate often re-dosed with terpenes. Full-spectrum preserves the source plant’s original profile. Neither is superior; they serve different purposes. The consumer should simply know which one they are buying, and labels do not always make it obvious.
Product Testing — Reading a Certificate of Analysis
Full Entry
The THC number on the front of the package is not what most people think it is, and it is not the best predictor of quality.
The Total THC math
Most flower contains THCA, the acid form, which converts to THC when heated. Total THC = (THCA × 0.877) + THC, with the factor accounting for weight lost during decarboxylation. A product labelled 25% THCA is roughly 21.9% Total THC once converted. The headline number lives on the front; the math lives in the fine print.
Why terpenes predict quality better than THC
Terpene content is a stronger signal of subjective quality than THC percentage. Above 2% total terpenes usually indicates a well-grown, properly cured product; below 1% is flat. The market’s fixation on THC percentage trained consumers to chase the wrong number.
What the lab panel guarantees
Health Canada requires licensed producers to test for cannabinoid potency, microbial contamination, heavy metals, pesticides, and residual solvents, within defined tolerance bands[1]. The certificate tells you what was in the submitted sample. Our reviews test what was in the package you actually bought.
Terpenes are the aromatic compounds that give each cultivar its smell and much of its character. They are not unique to cannabis — the same molecules are behind pine, citrus, and lavender — and they may shape the experience more than the THC number does.
Terpene Reference Chart
Terpene
Aroma
Also found in
Associated character
Boils at*
Myrcene
Earthy, musky, clove
Mango, hops, thyme
Most common in cannabis; relaxed profile
~167°C
Limonene
Bright citrus
Lemon & orange peel
Associated with mood lift
~176°C
Caryophyllene
Peppery, spicy
Black pepper, cloves
The one terpene that binds CB2 receptors
~130°C
Pinene
Sharp pine
Pine, rosemary, basil
Associated with alertness
~155°C
Linalool
Floral
Lavender
Associated with calm
~198°C
Humulene
Hoppy, woody
Hops, coriander
Earthy; often paired with caryophyllene
~106°C
Terpinolene
Fresh, herbal-floral
Apple, nutmeg, cumin
Common in many “sativa”-labelled cultivars
~185°C
*Approximate boiling points, commonly cited. They matter for vaporizer temperature and for why heat and time degrade aroma — which is exactly why storage matters.
The entourage effect — and its limits
The “entourage effect” is the hypothesis that cannabinoids and terpenes act together to shape the overall effect. There is real preliminary support, but it remains an area of active research, not settled fact. We treat it as promising, not proven.
Storage & Shelf Stability — Is 62% the Right Humidity?
Short answer: yes, 62% relative humidity is the most widely used target, and it is a sound default. The practical ideal sits in a 55–65% RH band, and 62% lands near the middle of it.
Below ~55% terpenes evaporate, harsh
55–65% RH SHELF-STABLE
Above ~65% mould risk
45%55%62%65%75%
Common retail two-way packs hold 62%; some prefer 58% for a drier feel and a wider mould-safety margin.
At 62% the flower stays supple, the volatile terpenes are preserved, and the burn stays smooth. Drift too dry and those aromatics evaporate, leaving harsh, dusty flower; climb too humid and you invite mould. Two-way humidity packs hold the buffer in either direction.
Humidity is only half of it. Pair it with cool, dark, and airtight — ideally glass. Light and heat degrade cannabinoids and terpenes faster than anything else, which is why a clear jar on a sunny shelf is the fastest way to waste good flower[1].
Why it matters at the counter
Total terpene content above 2% generally signals careful cultivation and curing; a flat profile often means the aromatics were lost to poor handling or were never there. Reading terpenes — and storing them properly once you get them home — is how you move past the THC number toward what actually makes a product good.
[5] Gobbi G, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood. JAMA Psychiatry. 2019. doi:10.1001/jamapsychiatry.2018.4500 [6] Grimison P, et al. Oral Cannabis Extract for Chemotherapy-Induced Nausea and Vomiting (Phase II/III RCT). J Clin Oncol. 2024. doi:10.1200/JCO.23.01836 [7] Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. CMAJ. 2020. doi:10.1503/cmaj.191097
Flagged: as each "Expanding" entry is built out, its specific primary citations get added here. The citation rail is the standard for every Deep Dive.
